학술논문
EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France.
Document Type
Article
Author
Source
Subject
Language
ISSN
1098-3015